James Gordon CFA

Stock Analyst at Barclays

(3.12)
# 2,449
Out of 4,334 analysts
109
Total ratings
52.6%
Success rate
6%
Average return

Stocks Rated by James Gordon CFA

Genmab A/S
May 22, 2026
Rated: Buy
Price Target: $2,500
Current: $1,723.63
Upside: +45.04%
Novo Nordisk A/S
May 19, 2026
Maintained: Hold
Price Target: $300
Current: $289.00
Upside: +3.81%
Galderma Group AG
May 18, 2026
Maintained: Buy
Price Target: $200
Current: $158.65
Upside: +26.06%
argenx SE
May 11, 2026
Reiterated: Buy
Price Target: $900
Current: $697.71
Upside: +28.99%
Sandoz Group AG
May 5, 2026
Upgraded: Buy
Price Target: $75
Current: $64.44
Upside: +16.39%
AstraZeneca PLC
Apr 29, 2026
Maintained: Buy
Price Target: $165
Current: $13,916.00
Upside: -98.81%
GSK plc
Apr 28, 2026
Maintained: Sell
Price Target: $19
Current: $1,915.00
Upside: -99.01%
Roche Holding AG
Apr 28, 2026
Maintained: Buy
Price Target: $410
Current: $334.50
Upside: +22.57%
Novartis AG
Apr 28, 2026
Maintained: Hold
Price Target: $120
Current: $119.46
Upside: +0.45%
Sanofi
Apr 23, 2026
Maintained: Hold
Price Target: $85
Current: $77.46
Upside: +9.73%
Maintained: Sell
Price Target: $14
Current: $1,459.00
Upside: -99.07%